Turmeric is one of the most studied ingredients in traditional medicine and, in the last twenty years, also in pharmacology and clinical nutrition. But there is a fundamental problem that has limited its practical application for decades: curcuminoids—the active compounds in turmeric—have extremely low oral bioavailability in their standard form. The story of HydroCurc® is the story of how technology solved this problem.
Curcuminoids: what they are and what mechanisms they activate
Curcuminoids are the polyphenolic pigments that give turmeric (Curcuma longa) its intense yellow color. The main one is curcumin (approximately 75-80% of the total), followed by demethoxycurcumin and bisdemethoxycurcumin. Their mechanisms of action include the inhibition of NF-kB (the transcription factor that regulates the inflammatory response), the modulation of proinflammatory cytokines (IL-1β, IL-6, TNF-α), the inhibition of COX-1 and COX-2 cyclooxygenases, and direct antioxidant activity through the neutralization of free radicals.
In the cutaneous context, these mechanisms have direct relevance to inflammaging, the degradation of the extracellular matrix, and the inflammatory response associated with photodamage and chronic oxidative stress. The problem is that none of these effects can occur if the ingredient does not reach the tissues in sufficient concentration.
The problem of oral turmeric bioavailability
Standard curcumin has several characteristics that dramatically limit its oral bioavailability: it is poorly water-soluble (lipophilic), it undergoes rapid degradation in the alkaline pH of the small intestine, and it experiences very intense first-pass hepatic metabolism. The result is that, in its conventional form, only a minimal fraction of ingested curcumin reaches systemic circulation.
This problem has generated an industry of technological solutions: formulas with piperine (which inhibits hepatic metabolism), nanoparticles, phospholipid complexes and, more recently, aqueous dispersion technologies such as LipiSperse®. Each has advantages and disadvantages, and their clinical results are variable.
HydroCurc®: the technological solution with published evidence
HydroCurc® is a patented form of curcuminoids developed by Gencor using LipiSperse® technology, which converts lipophilic curcumin into a water-dispersible form without the need for additional lipid excipients. This technology significantly improves the dispersion of the ingredient in the digestive tract, increasing the contact surface with the intestinal mucosa and, therefore, absorption.
Comparative bioavailability studies have shown that HydroCurc® can achieve significantly higher plasma concentrations of curcuminoids than standard curcumin. A trial by Dei Cas & Ghidoni (2019) published in Nutrients documented the improved bioavailability of HydroCurc® compared to standard turmeric extract. LEVIAL includes 21.25 mg of HydroCurc® with 85% curcuminoids per vial.
What research says about inflammation, skin, and oxidative stress
Studies with bioavailable curcuminoids on parameters related to systemic inflammation and skin show results in modulating inflammatory markers, reducing oxidative stress, and, in some studies, improving skin parameters. The anti-inflammatory activity of curcuminoids is one of the most robustly documented mechanisms in pharmacological literature.
In the context of inflammaging—the chronic low-grade inflammation that accelerates aging—curcuminoids with high bioavailability represent a nutritional intervention with sound logic. They do not replace medical treatment but contribute to modulating the systemic inflammatory environment from which skin deterioration originates.
